A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 32, Issue 6, 2003, Pages 557-561

  Shapira, M Y ^a   Or, R ^a   Resnick, I B ^a   Bitan, M ^a   Ackerstein, A ^a   Samuel, S ^a   Elad, S ^a   Zilberman, I ^a   Miron, S ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogenic stem cell transplantation; Hematologic malignancies; High risk patients; Leukemia; Nonmyeloablative stem cell transplantation (NST); Reduced intensity conditioning

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMIKACIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; BUSULFAN; CEFAZOLIN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; G NEUPOGEN; GANCICLOVIR; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MEROPENEM; METHYLPREDNISOLONE; MEZLOCILLIN; MYELOABLATIVE AGENT; PIPERACILLIN PLUS TAZOBACTAM; THYMOCYTE ANTIBODY; TRIMETHOPRIM; VANCOMYCIN;

ADULT; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; BONE MARROW APLASIA; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CELL LINEAGE; CHIMERA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM; HIGH RISK PATIENT; HOST; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LOW DRUG DOSE; LUNG DISEASE; LYMPHOCYTE; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; SHORT COURSE THERAPY; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION;

ADULT; BUSULFAN; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION; PILOT PROJECTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 10744223688     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704190     Document Type: Article

References (26)

1. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
2. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. Lancet Oncol 2001; 2: 491-498 (Review).
3. Champlin R, Khouri I, Kornblau S et al. Reinventing bone marrow transplantation. Non-myeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology 1999; 13: 621-628.
4. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
5. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
6. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-vs-host disease in human recipients of marrow from HLA-matched-sibling donors. Transplantation 1974; 18: 295-304.
7. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273-275.
8. Nakamura Y, Leppert O, O'Connel P et al. Variable number of tandem repeats (VNTR) markets for human gene mapping. Science 1987; 235: 1616-1622.
9. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-vs-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
10. Kapelushnik J, Or R, Slavin S, Nagler A. A fludarabine based protocol for bone marrow transplantation in Fanconi's anemia. Bone Marrow Transplant 1997; 20: 1109-1110.
11. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
12. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
13. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by non-myeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
14. Storb R. Non-myeloablative preparative regimens: how relevant for acute myelogenous leukemia? Leukemia 2001; 15: 662-663.
15. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77: 1660-1665.
16. Alyea E, Neuberg D, Mauch P et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002; 8: 139-144.
17. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
18. Weiden PL, Fluornoy N, Sanders JE et al. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981; 13: 248-251.
19. Weiden PL, Sullivan KM, Fluornoy N et al. Antileukemic effect of chronic graft-vs-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
20. Horowitz MM, Gale RP, Sondel PM et al. Graft-vs-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
21. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest 1992; 10: 19-26.
22. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S. Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 1995; 23: 196-201.
23. Ji YH, Weiss L, Zeira M et al. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to up-regulate anti-tumor effects and down-regulate anti-host responses. Bone Marrow Transplant, in press.
24. Morecki A, Levi S, Puyesky Y, Slavin S. Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell surface idiotype and the costimulatory B7 molecule. Cancer Immunol Immunother 1995; 41: 236-242.
25. Morecki S, Yacovlev E, Gelfand Y et al. Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother 2001; 24: 114-121.
26. Slavin S, Ackerstein A, Morecki S et al. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigens pulsed donor lymphocytes. Bone Marrow Transplant 2001; 28: 795-798.